New drug cocktail aims to fight advanced cancers
NCT ID NCT01334073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how well the tumors responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib plus everolimus (two oral drugs taken daily)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors, especially kidney cancer, by shrinking tumors or slowing their growth.
What could go wrong
This is a very early Phase 1 trial with only 19 participants, focused on finding a safe dose. The combination may cause significant side effects and may not prove effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Professeur Alain RAVAUD
Bordeaux, 33000, France
-
Professeur Jean-Pierre DELORD
Toulouse, 31000, France